BEDMINSTER, N.J., Nov. 22 /PRNewswire-FirstCall/ -- Bioject Medical
Technologies Inc. (Nasdaq: BJCT), a leading developer of needle-free drug
delivery systems, announced today that it has received a Small Business
Innovation Research (SBIR) contract from the Centers of Disease Control and
Prevention (CDC) to build and test a prototype of a needle-free single-dose
injection delivery system featuring auto-disabling disposable-cartridges and a
jet injector device.
Designed to be sturdy and economical for use in developing country
immunization programs, the jet injector system will also be suitable for
doctor's offices in developed countries. The system consists of a durable,
manually-powered, mechanical device, requiring no electricity, batteries, or
other external supply of power. Its sterile cartridge, once filled and used
for a single injection, cannot be refilled and is disposed safely without
exposing health workers to needlestick "sharps" injuries.
A similar proof-of-concept jet injector was evaluated by focus groups of
health care workers in Africa, whose feedback contributed to the design of the
new device. For the purposes of this SBIR contract, Bioject plans to build
and test prototypes for safely and effectively delivering subcutaneous,
intramuscular and intradermal injections of vaccines and potentially other
liquid pharmaceuticals.
"We are pleased to have received a contract from the CDC for the
development of an immunization device with an auto-disabling needle free
cartridge," said Jim O'Shea, Chairman, President and CEO of Bioject. "The
initial prototypes to be developed under this contract will be used to conduct
in vitro and in vivo studies that will demonstrate that our new needle-free
technology with non-reusable cartridges can meet safely the challenges of
global immunization."
About Bioject
Bioject Medical Technologies Inc., based in Bedminster, New Jersey, with
operations in Portland, Oregon, is an innovative developer and manufacturer of
needle-free drug delivery systems. Needle-free injection works by forcing
medication at high speed through a tiny orifice held against the skin. This
creates a fine stream of high-pressure fluid that penetrates the skin and
deposits vaccine in the tissue beneath. Bioject is focused on developing
mutually beneficial agreements with leading pharmaceutical, biotechnology, and
veterinary companies.
For more information about Bioject, visit http://www.bioject.com.
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Such forward-looking
statements involve known and unknown risks, uncertainties and other factors
that may cause the actual results, performance or achievements of the Company,
or industry results, to be materially different from any future results,
performance, or achievements expressed or implied by such forward-looking
statements. Such risks, uncertainties and other factors include, without
limitation, the risk that the products will not be accepted by the market,
uncertainties related to the time required for the Company to complete
research and development, obtain necessary clinical data and government
clearances, the risk that the Company may be unable to produce our products at
a unit cost necessary for the products to be competitive in the market and the
risk that the Company may be unable to comply with the extensive government
regulations applicable to Bioject's business. Readers of this press release
are referred to the Company's filings with the Securities and Exchange
Commission, including the Company's reports on Form 10-K and Forms 10-Q for
further discussions of factors that could affect the Company's business and
its future results. Forward-Looking statements are based on the estimates and
opinions of management on the date the statements are made. The Company
assumes no obligation to update forward-looking statements if conditions or
management's estimates or opinions should change.
SOURCE Bioject Medical Technologies Inc.
 back to top
Related links:
http://www.bioject.com
CONTACT:
John Gandolfo, Chief Financial Officer of
Bioject Medical Technologies Inc., +1-908-470-2800, ext. 5102, or
jgandolfo@bioject.com; or John Baldissera of BPC Financial
Marketing, 1-800-368-1217, for Bioject Medical Technologies Inc.
|
